BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 10350253)

  • 41. Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity.
    Giezeman-Smits KM; Okada H; Brissette-Storkus CS; Villa LA; Attanucci J; Lotze MT; Pollack IF; Bozik ME; Chambers WH
    Cancer Res; 2000 May; 60(9):2449-57. PubMed ID: 10811123
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Granulocyte-macrophage colony-stimulating factor stimulates arteriogenesis in a pig model of peripheral artery disease using clinically applicable infusion pumps.
    Grundmann S; Hoefer I; Ulusans S; Bode C; Oesterle S; Tijssen JG; Piek JJ; Buschmann I; van Royen N
    J Vasc Surg; 2006 Jun; 43(6):1263-9. PubMed ID: 16765251
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Use of continuous infusion granulocyte-macrophage colony-stimulating factor alone or followed by granulocyte colony-stimulating factor to enhance engraftment following high-dose chemotherapy and autologous bone marrow transplantation for lymphoid malignancies.
    Vose JM; Bierman PJ; Ruby E; Reed EC; Bishop MR; Tarantolo S; Kessinger A; Armitage JO
    Bone Marrow Transplant; 1996 Jun; 17(6):951-6. PubMed ID: 8807099
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nonspecific immunotherapy with intratumoral lipopolysaccharide and zymosan A but not GM-CSF leads to an effective anti-tumor response in subcutaneous RG-2 gliomas.
    Mariani CL; Rajon D; Bova FJ; Streit WJ
    J Neurooncol; 2007 Dec; 85(3):231-40. PubMed ID: 17568998
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Particle-mediated gene transfer of granulocyte-macrophage colony-stimulating factor cDNA to tumor cells: implications for a clinically relevant tumor vaccine.
    Mahvi DM; Burkholder JK; Turner J; Culp J; Malter JS; Sondel PM; Yang NS
    Hum Gene Ther; 1996 Aug; 7(13):1535-43. PubMed ID: 8864754
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment with tumor necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor increases epidermal Langerhans' cell numbers in cancer patients.
    Janik JE; Miller LL; Kopp WC; Taub DD; Dawson H; Stevens D; Kostboth P; Curti BD; Conlon KC; Dunn BK; Donegan SE; Ullrich R; Alvord WG; Gause BL; Longo DL
    Clin Immunol; 1999 Dec; 93(3):209-21. PubMed ID: 10600331
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.
    von Mehren M; Arlen P; Gulley J; Rogatko A; Cooper HS; Meropol NJ; Alpaugh RK; Davey M; McLaughlin S; Beard MT; Tsang KY; Schlom J; Weiner LM
    Clin Cancer Res; 2001 May; 7(5):1181-91. PubMed ID: 11350882
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mobilization of peripheral blood stem cells by subcutaneous injections of yeast-derived granulocyte macrophage colony stimulating factor: a phase I-II study.
    Mangan K; Mullaney M; Klumpp T; Goldberg S; Macdonald J
    Stem Cells; 1993 Sep; 11(5):445-54. PubMed ID: 8241955
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antitumoral vaccination with granulocyte-macrophage colony-stimulating factor or interleukin-12-expressing DHD/K12 colon adenocarcinoma cells.
    Lechanteur C; Moutschen M; Princen F; Lopez M; Franzen E; Gielen J; Bours V; Merville MP
    Cancer Gene Ther; 2000 May; 7(5):676-82. PubMed ID: 10830715
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A thermal gel depot for local delivery of paclitaxel to treat experimental brain tumors in rats.
    Tyler B; Fowers KD; Li KW; Recinos VR; Caplan JM; Hdeib A; Grossman R; Basaldella L; Bekelis K; Pradilla G; Legnani F; Brem H
    J Neurosurg; 2010 Aug; 113(2):210-7. PubMed ID: 20001591
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma.
    Sandler AD; Chihara H; Kobayashi G; Zhu X; Miller MA; Scott DL; Krieg AM
    Cancer Res; 2003 Jan; 63(2):394-9. PubMed ID: 12543793
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Autocrine growth regulation by granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor in human gliomas with tumor progression.
    Mueller MM; Herold-Mende CC; Riede D; Lange M; Steiner HH; Fusenig NE
    Am J Pathol; 1999 Nov; 155(5):1557-67. PubMed ID: 10550313
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The effect of granulocyte macrophage-colony stimulating factor on bacterial translocation after administration of 5-fluorouracil in rats.
    Kucuk C; Ozkan M; Akgun H; Muhtaroglu S; Sozuer E
    J Surg Res; 2005 Sep; 128(1):15-20. PubMed ID: 15975592
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intratumoral COX-2 inhibition enhances GM-CSF immunotherapy against established mouse GL261 brain tumors.
    Eberstål S; Sandén E; Fritzell S; Darabi A; Visse E; Siesjö P
    Int J Cancer; 2014 Jun; 134(11):2748-53. PubMed ID: 24243648
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cure of established GL261 mouse gliomas after combined immunotherapy with GM-CSF and IFNgamma is mediated by both CD8+ and CD4+ T-cells.
    Smith KE; Fritzell S; Badn W; Eberstål S; Janelidze S; Visse E; Darabi A; Siesjö P
    Int J Cancer; 2009 Feb; 124(3):630-7. PubMed ID: 18972433
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Synergism between cryoablation and GM-CSF: enhanced immune function of splenic dendritic cells in mice with glioma.
    Xu H; Wang Q; Lin C; Yin Z; He X; Pan J; Lu G; Zhang S
    Neuroreport; 2015 Apr; 26(6):346-53. PubMed ID: 25735009
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Local intracerebral delivery of endogenous inhibitors by osmotic minipumps effectively suppresses glioma growth in vivo.
    Giussani C; Carrabba G; Pluderi M; Lucini V; Pannacci M; Caronzolo D; Costa F; Minotti M; Tomei G; Villani R; Carroll RS; Bikfalvi A; Bello L
    Cancer Res; 2003 May; 63(10):2499-505. PubMed ID: 12750272
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intradermal injection of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with metastatic melanoma recruits dendritic cells.
    Nasi ML; Lieberman P; Busam KJ; Prieto V; Panageas KS; Lewis JJ; Houghton AN; Chapman PB
    Cytokines Cell Mol Ther; 1999 Sep; 5(3):139-44. PubMed ID: 10641571
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.